BioCryst to Present at JMP Securities Hematology Summit
December 11 2020 - 07:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that
the company will present at the JMP Securities Hematology Summit,
which is being conducted as a virtual event, on Tuesday, December
15, 2020 at 3:30 p.m. ET.
Links to a live audio webcast and replay of the
presentation may be accessed in the Investors section of BioCryst’s
website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. Oral, once-daily
ORLADEYO™ (berotralstat) is approved in the United States for the
prevention of HAE attacks in adults and pediatric patients 12 years
and older, and under regulatory review for approval in Japan and
the European Union. BioCryst has several ongoing development
programs including BCX9930, an oral Factor D inhibitor for the
treatment of complement-mediated diseases, galidesivir, a potential
treatment for COVID-19, Marburg virus disease and Yellow Fever, and
BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia
ossificans progressiva. RAPIVAB® (peramivir injection), a
viral neuraminidase inhibitor for the treatment of influenza, is
BioCryst’s first approved product and has received regulatory
approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
Post-marketing commitments for RAPIVAB are ongoing. For more
information, please visit the Company’s website
at www.biocryst.com.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2023 to Mar 2024